Evercore Cuts Insulet (NASDAQ:PODD) Price Target to $240.00

Insulet (NASDAQ:PODD) had its price objective reduced by Evercore from $340.00 to $240.00 in a research note released on Monday morning,MarketScreener reports. Evercore currently has an outperform rating on the medical instruments supplier’s stock.

Other equities analysts have also issued reports about the stock. The Goldman Sachs Group cut their price target on shares of Insulet from $363.00 to $326.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Oppenheimer dropped their target price on Insulet from $365.00 to $300.00 and set an “outperform” rating on the stock in a research note on Thursday, February 19th. Barclays restated an “underweight” rating and set a $286.00 target price on shares of Insulet in a research note on Thursday, February 19th. Truist Financial dropped their target price on Insulet from $390.00 to $360.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Finally, Sanford C. Bernstein dropped their target price on Insulet from $380.00 to $330.00 and set an “outperform” rating on the stock in a research note on Thursday, February 19th. Nineteen investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $342.00.

Insulet Trading Up 0.5%

Shares of NASDAQ:PODD opened at $203.51 on Monday. Insulet has a 12-month low of $198.10 and a 12-month high of $354.88. The business’s fifty day simple moving average is $234.54 and its 200-day simple moving average is $281.44. The company has a market capitalization of $14.33 billion, a PE ratio of 58.15, a P/E/G ratio of 1.22 and a beta of 1.47. The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The business had revenue of $783.80 million for the quarter, compared to the consensus estimate of $768.31 million. During the same period last year, the business posted $1.15 EPS. The business’s revenue was up 31.2% compared to the same quarter last year. As a group, equities research analysts predict that Insulet will post 3.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Michael R. Minogue purchased 2,030 shares of the stock in a transaction on Wednesday, February 25th. The stock was bought at an average price of $246.23 per share, with a total value of $499,846.90. Following the transaction, the director owned 17,483 shares in the company, valued at $4,304,839.09. The trade was a 13.14% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.39% of the stock is currently owned by company insiders.

Institutional Trading of Insulet

Large investors have recently added to or reduced their stakes in the company. Larson Financial Group LLC grew its stake in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in Insulet during the 4th quarter valued at about $26,000. True Wealth Design LLC grew its stake in Insulet by 288.0% during the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 72 shares during the last quarter. DV Equities LLC purchased a new stake in Insulet during the 4th quarter valued at about $28,000. Finally, Elyxium Wealth LLC purchased a new stake in Insulet during the 4th quarter valued at about $28,000.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Analysts maintain overall constructive view — the street consensus is a “moderate buy,” which supports demand even as some targets reset. Insulet Corporation (NASDAQ:PODD) Receives Consensus Recommendation of “Moderate Buy” from Analysts
• Positive Sentiment: Management hire: Insulet named Mike Panos as Chief Commercial Officer — a reinforcement for sales/commercial strategy that investors often view positively for growth companies. Insulet (PODD) Appoints Mike Panos as Chief Commercial Officer
• Positive Sentiment: Bullish coverage in retail lists: Insulet was named among small sets of stocks expected to “explode” over the next 3 years — a retail/idea flow positive that can attract momentum buyers. 5 Stocks Set to Explode in the Next 3 Years
• Neutral Sentiment: Goldman trimmed its price target to $277 from $326 but kept a “buy” rating — less upside implied but still supportive of the growth story. Goldman Sachs adjusts price target on Insulet to 277 from 326; maintains buy rating
• Neutral Sentiment: Evercore cut its target to $240 (from $340) but retained an “outperform” rating — another downward re‑calibration of expectations without a sell verdict. Evercore ISI adjusts Insulet PT to 240 from 340; maintains outperform rating
• Negative Sentiment: Downgrade: Citigroup moved PODD from “buy” to “neutral” and cut its target to $230 — a clear near-term headwind for sentiment and potential selling pressure. Citigroup downgrades Insulet (PODD)
• Negative Sentiment: Investor litigation alert: Pomerantz LLP announced an investigation into Insulet investor claims — increased legal/uncertainty risk that can amplify downside if issues develop. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet Corporation – PODD

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.